Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation

Schmaldienst S, Oberpichler A, Tschesche H, Horl WH (2003)
KIDNEY & BLOOD PRESSURE RESEARCH 26(2): 107-112.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Autor/in
; ; ;
Abstract / Bemerkung
Degranulation of polymorphonuclear leukocytes (PMNL) occurs during extracorporeal circulation. A degranulation-inhibiting protein identical to angiogenin was recently isolated from high-flux dialyzer ultrafiltrate. This protein inhibits the release of lactoferrin and metalloproteinases from PMNL in vitro. In the present study, we investigated end-stage renal disease patients undergoing regular hemodialysis treatment with either high-flux dialyzers (n = 51) or low-flux dialyzers (n = 44), and chronically uremic patients undergoing hemodiafiltration (n = 30). Hemodialysis therapy with low-flux polysulfone or cellulose triacetate membranes caused no or only minimal reduction (less than or equal to8%) of plasma angiogenin levels within 2 h of dialysis treatment associated with a 1.6-fold lactoferrin release from PMNL. Hemodialysis therapy with high-flux membranes (e.g. cellulose triacetate, polymethylmethacrylate) or hemodiafiltration resulted in a reduction of plasma angiogenin levels by 20-40% after 2 h associated with a nearly 4-fold PMNL lactoferrin release. The release of PMNL elastase was not affected by the different treatment modalities used. We conclude that high angiogenin plasma levels protect against lactoferrin release from PMNL during extracorporeal circulation in chronically uremic patients. A decrease of plasma angiogenin between 20 and 40% during extracorporeal circulation, however, results in marked PMNL lactoferrin release. This novel mechanism may explain, at least in part, PMNL degranulation also in non complement activating high-flux membranes. Copyright (C) 2003 S. Karger AG, Basel.
Stichworte
hemodialysis; polymorphonuclear leukocytes; elastase; hemodiafiltration
Erscheinungsjahr
2003
Zeitschriftentitel
KIDNEY & BLOOD PRESSURE RESEARCH
Band
26
Ausgabe
2
Seite(n)
107-112
ISSN
1420-4096
eISSN
1423-0143
Page URI
https://pub.uni-bielefeld.de/record/1611184

Zitieren

Schmaldienst S, Oberpichler A, Tschesche H, Horl WH. Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation. KIDNEY & BLOOD PRESSURE RESEARCH. 2003;26(2):107-112.
Schmaldienst, S., Oberpichler, A., Tschesche, H., & Horl, W. H. (2003). Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation. KIDNEY & BLOOD PRESSURE RESEARCH, 26(2), 107-112. doi:10.1159/000070992
Schmaldienst, S., Oberpichler, A., Tschesche, H., and Horl, W. H. (2003). Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation. KIDNEY & BLOOD PRESSURE RESEARCH 26, 107-112.
Schmaldienst, S., et al., 2003. Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation. KIDNEY & BLOOD PRESSURE RESEARCH, 26(2), p 107-112.
S. Schmaldienst, et al., “Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation”, KIDNEY & BLOOD PRESSURE RESEARCH, vol. 26, 2003, pp. 107-112.
Schmaldienst, S., Oberpichler, A., Tschesche, H., Horl, W.H.: Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation. KIDNEY & BLOOD PRESSURE RESEARCH. 26, 107-112 (2003).
Schmaldienst, S, Oberpichler, A, Tschesche, Harald, and Horl, WH. “Angiogenin: A novel inhibitor of neutrophil lactoferrin release during extracorporeal circulation”. KIDNEY & BLOOD PRESSURE RESEARCH 26.2 (2003): 107-112.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 12771535
PubMed | Europe PMC

Suchen in

Google Scholar